This segment encompasses the core activities of Shenyang Xingqi Pharmaceutical, focusing on the research, development, and manufacturing of a wide range of ophthalmic drugs. These include treatments for corneal diseases, anti-bacterial infections, artificial tears for dry eye, anti-inflammatory medications, surgical perfusates, mydriatics, and anti-fatigue solutions. The company employs advanced pharmaceutical technologies and methodologies to ensure the quality and efficacy of its products. R&D efforts are directed towards innovating new formulations and delivery systems to improve patient outcomes and address unmet needs in eye care. The segment's market positioning is strengthened by its focus on innovation and quality, allowing it to compete effectively in the Chinese pharmaceutical market. Future growth potential lies in expanding its product portfolio and exploring international markets.